The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion
Open accessAbstract
BACKGROUND: More than 50 years after the introduction of corticosteroids, few studies have focused on corticosteroid-induced adverse events after long-term systemic therapy. OBJECTIVES: To assess the frequency, risk factors and patient's opinion regarding clinical adverse events occurring early during prednisone therapy. PATIENTS AND METHODS: We conducted a cohort study in two French centres. All consecutive patients starting long-term (> oir = 3 months), high dosage (> or = 20 mg day(-1)) prednisone therapy were enrolled. The main clinical adverse events attributable to corticosteroids were assessed after 3 months of therapy, by comparison with baseline status. The patient's opinion regarding the disability induced by these adverse events was recorded. Risk factors of frequently observed adverse effects were identified by using logistic regression. RESULTS: Eighty-eight patients were enrolled and 80 were monitored for at least 3 months (women 76%; mean age 59.1 +/- 18.7 years; giant cell arteritis 39%; mean baseline prednisone dosage 54 +/- 17 mg day(-1)). Lipodystrophy was the most frequent adverse event [63.0% (51.0-73.1)], was considered the most distressing by the patients and was most frequent in women and young patients. Neuropsychiatric disorders occurred in 42 patients [52.5% (41.0-63.8)], necessitating hospitalization in five cases. Skin disorders were noted by 37 patients [46.2% (35.0-57.7)] and were more frequent in women. Muscle cramp and proximal muscle weakness were reported by 32.5% (22.5-43.9) and 15% (8.0-24.7) of patients, respectively. Newly developed hypertension occurred in 8.7% (2.9-20.3) of patients. Lastly, 39% (19.7-61.4) of the premenopausal women reported menstrual disorders. CONCLUSIONS: Lipodystrophy and neuropsychiatric disorders are common adverse events of long-term prednisone therapy and are particularly distressing for the patients concerned. The impact of these adverse events on adherence to corticosteroid therapy is not known.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Grinspoon, S., & Carr, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041811 · Cited by 1,070
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
Saag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B., Kohler, J. A., & Furst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540
van Everdingen, A. A., Jacobs, J. W. G., Siewertsz van Reesema, D. R., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 489
Association of Adrenocorticosteroid Therapy and Peptic-Ulcer Disease
Messer, J., Reitman, D., Sacks, H. S., Smith, H., & Chalmers, T. C. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307073090105 · Cited by 422
Laan, R. F. J. M., van Riel, P. L. C. M., van de Putte, L. B. A., van Erning, L. J. T. O., van't Hof, M. A., & Lemmens, J. A. M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00001 · Cited by 411
Bone loss in response to long-term glucocorticoid therapy
LoCascio, V., Bonucci, E., Imbimbo, B., Ballanti, P., Adami, S., Milani, S., Tartarotti, D., & DellaRocca, C. (1990) · Bone and Mineral · doi:10.1016/0169-6009(91)90139-q · Cited by 384
Walsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Rheumatoid arthritis, corticosteroid therapy and hip fracture.
Cooper, C., Coupland, C., & Mitchell, M. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.1.49 · Cited by 352
Presentation of the Steroid Psychoses
HALL, R. C. W., POPKIN, M. K., STICKNEY, S. K., & GARDNER, E. R. (1979) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197904000-00006 · Cited by 350
Corticosteroid-induced cataracts
Urban, R. C., & Cotlier, E. (1986) · Survey of Ophthalmology · doi:10.1016/0039-6257(86)90077-9 · Cited by 346
Acute adverse reactions to prednisone in relation to dosage
Program, T. B. C. D. S. (1972) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1972135part1694 · Cited by 335
Oral budesonide is as effective as oral prednisolone in active Crohn’s disease
Campieri, M., Ferguson, A., Doe, W., Persson, T., Nilsson, L.-G., & the Global Budesonide Study Group (1997) · Gut · doi:10.1136/gut.41.2.209 · Cited by 324
Corticosteroids and peptic ulcer: meta‐analysis of adverse events during steroid therapy
CONN, H. O., & POYNARD, T. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00855.x · Cited by 312
McEVOY, C. E., ENSRUD, K. E., BENDER, E., GENANT, H. K., YU, W., GRIFFITH, J. M., & NIEWOEHNER, D. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.3.9703080 · Cited by 285
HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management
Carr, A. (2003) · AIDS · doi:10.1097/00002030-200304001-00017 · Cited by 275
Caporali, R., Cimmino, M. A., Ferraccioli, G., Gerli, R., Klersy, C., Salvarani, C., Montecucco, C., & for the Systemic Vasculitis Study Group of the Italian Society for Rheumatology (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-7-200410050-00005 · Cited by 261
Risk Factors for Cortical, Nuclear, and Posterior Subcapsular Cataracts: The POLA Study
Delcourt, C., Cristol, J.-P., Tessier, F., Leger, C. L., Michel, F., Papoz, L., & the POLA Study Group (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010235 · Cited by 261
Adverse effects of oral corticosteroids in relation to dose in patients with lung disease
Walsh, L. J. (2001) · Thorax · doi:10.1136/thorax.56.4.279 · Cited by 253
Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica
Gabriel, S. E., Sunku, J., Salvarani, C., O'Fallon, W. M., & Hunder, G. G. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401022 · Cited by 239
Budesonide versus prednisone in the treatment of active Crohn's disease
Bar–Meir, S., Chowers, Y., Lavy, A., Abramovitch, D., Sternberg, A., Leichtmann, G., Reshef, R., Odes, S., Moshkovitz, M., Bruck, R., et al. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70254-9 · Cited by 211
Kelly, J., Mangos, G., Williamson, P., & Whitworth, J. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02301.x · Cited by 204
Steroid myopathy in cancer patients
Batchelor, T. T., Taylor, L. P., Thaler, H. T., Posner, J. B., & DeAngelis, L. M. (1997) · Neurology · doi:10.1212/wnl.48.5.1234 · Cited by 187
Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids
Garbe, E., LeLorier, J., Boivin, J.-F., & Suissa, S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03392-8 · Cited by 181
Steroids and Risk of Upper Gastrointestinal Complications
Hernández–Dı́az, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.11.1089 · Cited by 145
Smyllie, H. C., & Connolly, C. K. (1968) · Thorax · doi:10.1136/thx.23.6.571 · Cited by 126
Chronic Glucocorticoid Therapy-Induced Osteoporosis in Patients With Obstructive Lung Disease
Goldstein, M. F., Fallon, J. J., & Harning, R. (1999) · CHEST Journal · doi:10.1378/chest.116.6.1733 · Cited by 100
Corticosteroid-associated complications in elderly Crohn's disease patients.
Akerkar, G. A., Peppercorn, M. A., Hamel, M. B., et al. (1997) · PubMed · Cited by 96
The Complications of Systemic Corticosteroid Therapy in the Elderly
Thomas, T. (2009) · Gerontology · doi:10.1159/000212608 · Cited by 94
Complications of long-term steroid therapy for asthma
Lieberman, P. L., Patterson, R., & Kunske, R. (1972) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(72)90131-5 · Cited by 89
A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis.
Homik, J., Cranney, A., Shea, B., Tugwell, P., Wells, G. A., Adachi, J. D., & Suarez-Almazor, M. E. (1999) · PubMed · Cited by 84
Is enough attention being given to the adverse effects of corticosteroid therapy?
Hougardy, Peterson, G. M., Bleasel, & Randall (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00284.x · Cited by 81
Prevention of Glucocorticoid-Induced Osteoporosis
Yood, R. A., Harrold, L. R., Fish, L. S., Cernieux, J., Emani, S., Conboy, E., & Gurwitz, J. H. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.10.1322 · Cited by 67
Glucocorticoid-induced hypertension: from mouse to man
Whitworth, J. A., Schyvens, C. G., Zhang, Y., Mangos, G. J., & Kelly, J. J. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03584.x · Cited by 66
Does Long-Term Low-Dose Corticosteroid Therapy Cause Hypertension?
Jackson, S. H. D., Beevers, D. G., & Myers, K. (1981) · Clinical Science · doi:10.1042/cs061381s · Cited by 64
Sato, A., Funder, J. W., Okubo, M., Kubota, E., & Saruta, T. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00149-j · Cited by 60
A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
Kirwan, J., Hällgren, R., Mielants, H., Wollheim, F. A., Bjorck, E., Persson, T., Book, C., Bowman, S., Byron, M., Cox, N., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.008573 · Cited by 53
Wolfe, F., & Hawley, D. J. (2000) · PubMed · Cited by 51
The cost of glucocorticoid-associated adverse events in rheumatoid arthritis
Pisu, M., James, N. I., Sampsel, S., & Saag, K. G. (2005) · Rheumatology · doi:10.1093/rheumatology/keh594 · Cited by 48
Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids
Morrison, E. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg355 · Cited by 47
Bae, S., Corzillius, M., Kuntz, K. M., & Liang, M. H. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/keg029 · Cited by 33
Chibane, S., Feldman-Billard, S., Rossignol, I., Kassaei, R., Mantout, F., & Héron, E. (2004) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2004.09.025 · Cited by 28
Montrella-Waybill, M., Clore, J. N., Schoolwerth, A. C., Watlington, C. O., Whitworth, J. A., & Kelly, J. J. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349774 · Cited by 20
The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis
Rizzato, G., Riboldi, A., Imbimbo, B. P., Torresin, A., & Milani, S. (1997) · Respiratory Medicine · doi:10.1016/s0954-6111(97)90109-8 · Cited by 20
Managing Corticosteroid Induced Osteoporosis in Medical Outpatients
Bell, R., Carr, A., & Thompson, P. W. (1997) · Journal of the Royal College of Physicians of London · doi:10.1016/s0035-8819(25)00231-4 · Cited by 20
Cited by
Long-term side effects of glucocorticoids
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1140743 · Cited by 869
Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586
The epidemiology of glucocorticoid-associated adverse events
McDonough, A. K., Curtis, J. R., & Saag, K. G. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f51031 · Cited by 405
A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids
Poetker, D. M., & Reh, D. D. (2010) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2010.04.003 · Cited by 337
Sweeney, J., Patterson, C. C., Menzies-Gow, A., Niven, R. M., Mansur, A. H., Bucknall, C., Chaudhuri, R., Price, D., Brightling, C. E., & Heaney, L. G. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207630 · Cited by 331
Metadata
- Authors
- Fardet, L., Flahault, A., Kettaneh, A., Tiev, K. P., Généreau, T., Tolédano, C., Lebbé, C., & Cabane, J.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07
- Volume
- 157
- Issue
- 1
- Pages
- 142-148
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2160936253
- Cited by
- 273
- References
- 48
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.